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Abstract 7-Deazaxanthine (7DX) was identified as a novel
inhibitor of thymidine (dThd) phosphorylase (TPase). It inhibited
the TPase reaction in a concentration-dependent manner. At
1 mM, it almost completely prevented the TPase-catalysed
hydrolysis of dThd to thymine. The 50% inhibitory concentration
(IC50) of 7DX was 40 WM in the presence of 100 WM of the
natural substrate dThd. 7DX is also endowed with a marked
inhibitory effect on angiogenesis. It significantly prevents
neovascularisation in the chicken chorioallantoic membrane
during development. 7DX is the first purine derivative shown to
be a potent inhibitor of purified TPase and angiogenesis.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
There exist at least two di¡erent pyrimidine nucleoside
phosphorylases that catalyse the conversion of pyrimidine (de-
oxy)nucleosides and structurally related analogues in mamma-
lian cells : thymidine phosphorylase (TPase; EC 2.4.2.4) and
uridine phosphorylase (UPase, EC 2.4.2.3). TPase is highly
speci¢c for the deoxyribosides of thymine and uracil ana-
logues. A variety of nucleoside analogues that are endowed
with antiviral activity (i.e. (E)-5-(2-bromovinyl)-2P-deoxyuri-
dine (BVDU), 5-tri£uoromethyl-2P-deoxyuridine (TFT), 5-
iodo-2P-deoxyuridine (IdU)) and antitumour activity (i.e. 5-
£uoro-2P-deoxyuridine (FdU)) are good substrates for TPase
[1]. Consequently, the presence of TPase activity in blood
(platelets) and in cells may cause a progressive inactivation
of these antiviral and anticancer agents (due to the catabolism
of the drugs), thereby preventing or diminishing the anabolic
conversion of the drugs to their biologically active metabo-
lites.
It has recently been shown that platelet-derived endothelial
cell growth factor (PD-ECGF) is endowed with TPase activity
[2^4], and that this enzymatic activity is crucial for the angio-
genic e¡ect [5^7]. Histological analysis of a variety of human
tumours including bladder [8], breast [9], oesophageal [10],
and colorectal cancers [11], have shown elevated PD-ECGF/
TPase levels. These levels correlated well with microvessel
density in breast [12], colon [11] oesophageal [10] and renal
cancers [13], providing evidence that PD-ECGF/TPase con-
tributes to the tumour vasculature [14]. Thus, PD-ECGF is
known to stimulate endothelial cell migration in vitro and
angiogenesis in vivo.
There is an urgent need for developing potent and selective
inhibitors of TPase, because they may potentiate the antiviral
activity of certain nucleoside analogues and/or they may be
endowed with anti-tumour (i.e. anti-angiogenic) activity. To
date, very few inhibitors of TPase have been described, 6-
aminothymine (6AT) and 6-amino-5-bromouracil (6A5BU)
ranking among the most potent [15].
In this report, we describe the ¢rst purine derivative (7-
deazaxanthine, 7DX) that shows inhibitory activity against
Escherichia coli TPase and that could be considered a novel
lead compound in the development of TPase inhibitors. Fur-
thermore, this compound was found to inhibit the angiogen-
esis in the chicken chorioallantoic membrane.
2. Materials and methods
2.1. Compound
The synthesis of 7-deazaxanthine was performed according to West
et al. [16]. Thymidine and thymine, and E. coli thymidine phospho-
rylase (TPase) (1030 units/ml) were obtained from Sigma (St. Louis,
MO). 6-Amino-5-bromouracil (6A5BU) was synthesised according to
E.F. Schroeder [17]. The structural formulae of the compounds are
depicted in Fig. 1.
2.2. TPase enzyme assay
The phosphorolysis of thymidine (dThd) by E. coli TPase was
measured by HPLC analysis. 1 ml of the incubation mixture con-
tained 10 mM Tris-HCl (pH 7.6), 1 mM EDTA, 2 mM potassium
phosphate, 150 mM NaCl, and 100 WM of thymidine in the presence
or absence of 100 WM 2-deoxyribose-K-1-phosphate (K-dR-1-P) and
0.05 units of TPase. Incubations were performed at 37‡C. At di¡erent
time points (i.e. 0, 10, 20, 40 and 60 min), 200-Wl fractions were taken,
brought into 1.5-ml Eppendorf tubes and rapidly cooled on ice. When
all samples were collected, they were transferred to an Eppendorf tube
thermo block and boiled at 95‡C for 5 min. The dThd was separated
from Thy and quanti¢ed in the samples by HPLC analysis.
In the assays where the inhibitory e¡ects of 6A5BU and 7DX were
evaluated, a variety of inhibitor concentrations, including 1 mM, 250
WM, 100 WM, 25 WM, 10 WM and 0 WM (control), were added to the
reaction mixture that contained 100 WM of dThd. Aliquots of 200 Wl
were withdrawn from the reaction mixture at several time points, as
described above, and analysed on HPLC.
2.3. Chorioallantoic membrane assay in fertilised chicken eggs
The chorioallantoic membrane (CAM) angiogenesis assay was per-
formed as originally described by Maragoudakis et al. [18]. Fertilised
eggs were incubated for 4 days at 37‡C. Then, a window of approx-
imately 1 cm2 was opened on the egg shell exposing the CAM, and
covered with cellophane tape. The eggs were further incubated at
37‡C for an additional 5 days (day 9) at which time the test com-
pounds (6A5BU and 7DX) were administered. The test compounds
were placed on sterile plastic discs (10 mm diameter) at 1 Wmol, 250
nmol and 100 nmol in DMSO and allowed to dry under sterile con-
ditions. The control discs (containing DMSO) were placed on the
CAM 1 cm away from the disc containing the test material. A sol-
ution of cortisone acetate (100 Wg/disc, Sigma, St. Louis, MO) was
incorporated in all discs to prevent an in£ammatory response. The
loaded and dried discs were inverted and placed on the CAM, the
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windows were covered with cellophane tape again, and the eggs fur-
ther incubated at 37‡C until day 11.
The eggs were then £ooded with 10% bu¡ered formalin (Janssen
Chimica, Geel, Belgium), the plastic discs were carefully removed and
the eggs were kept at room temperature for at least 4 h. A large area
around the discs was cut o¡ and placed on a glass slide, and the
vascular density index (expressed as the number of blood vessels)
was measured by the method of Harris-Hooker et al. [19]. This meth-
od allows an objective evaluation of microvessel formation, taking
into account the small newly formed microvessels.
3. Results
3.1. Design of 7DX
Since the three-dimensional structure of TPase from E. coli
has been determined at 2.8 Aî resolution [20], rational model-
ling and design of novel inhibitors of the enzyme has become
a feasible goal. The coordinates for the full-atom model of E.
coli TPase obtained crystallographically were kindly provided
by Dr. S. Ealick (Cornell University, NY). The well known
inhibitors 6A5BU and 6AT were modelled into the active site
based on the position of thymine inferred by Walter et al. [20].
Novel potential inhibitors of TPase were designed which pre-
served the structural features of these inhibitors, and their
interactions with TPase, as much as possible. The compound
7DX was one of these designs where the addition of the sec-
ond ring was intended to create extra stabilising interactions
by ¢lling the apparent space near the ring of residue Phe210.
3.2. Inhibitory e¡ect of 7DX against puri¢ed TPase
In a ¢rst set of experiments, 100 WM 7DX was added to a
reaction mixture containing equimolar amounts of dThd, and
the inhibitory e¡ect of 7DX on the TPase-catalysed conver-
sion of dThd to Thy+K-dR-1-P was examined. The well-
known TPase inhibitor 6A5BU was added for comparative
reasons in parallel experiments under similar experimental
conditions. The time-dependent dThd degradation in the pres-
ence of 100 WM 7DX or 6A5BU or in the absence of the
inhibitors is presented in Fig. 2. 7DX was found to be a
potent inhibitor of the TPase reaction. After 10 min, when
approximately 50% of dThd was converted to Thy in the
control reaction, dThd conversion was inhibited by 74% in
the presence of 7DX. At 20, 40 and 60 min, when dThd
conversion to Thy reached its equilibrium, the inhibitory po-
tential of 7DX progressively decreased from 68% (20 min) to
52% (40 min), eventually reaching 41% at 60 min. When the
potent TPase inhibitor 6A5BU was evaluated under similar
experimental conditions, the hydrolysis reaction was inhibited
by 91%, 88%, 82% and 76% after 10, 20, 40 and 60 min,
respectively, of incubation of the enzyme with 100 WM dThd
and 100 WM 6A5BU. Virtually identical values were obtained
when K-dR-1-P was added to the reaction mixture (data not
shown). It should also be mentioned that under our experi-
mental conditions, no signi¢cant conversion of 6A5BU and
7DX to their corresponding nucleoside derivatives was ob-
served on the HPLC chromatograms.
3.3. Concentration-inhibitory response of 7DX against
E. coli TPase
Di¡erent concentrations of 7DX and 6A5BU (i.e. 1 mM,
250 WM, 100 WM, 25 WM and 10 WM) were exposed to the
TPase reaction using 100 WM dThd as the natural substrate.
7DX prevented dThd hydrolysis by 96% at 1 mM and by 89%
at 250 WM after 10 min (Table 1); at the lower concentrations
(i.e. 25 and 10 WM), 7DX was still 43% and 25% inhibitory
(Table 1). At 60 min, when the control reaction had virtually
reached an equilibrium (completion), inhibition was still pro-
nounced at the high 7DX concentrations (91% and 73% at
1 mM and 250 WM, respectively) but less pronounced at the
lower concentrations (7% and 4% at 25 WM and 10 WM, re-
spectively) (Table 1). The 6A5BU derivative proved virtually
equipotent an inhibitor of the TPase reaction as 7DX at 250
WM, but superior to 7DX at lower concentrations (Table 1).
In both cases, the inhibitory e¡ect of 7DX and 6A5BU was
more pronounced when determined within 10 min of the en-
zyme reaction than within 60 min of the enzyme reaction
(Table 1).
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Fig. 1. Structural formulae of thymine (Thy), 6-aminothymine
(6AT), 6-amino-5-bromouracil (6A5BU) and 7-deazaxanthine
(7DX).
Fig. 2. Inhibition of TPase-mediated thymidine degradation (phos-
phorolysis) by 100 WM 6A5BU and 100 WM 7DX as a function of
incubation time. The initial thymidine concentration in the reaction
mixture was 100 WM.
J. Balzarini et al./FEBS Letters 438 (1998) 91^9592
3.4. Inhibitory e¡ect of 7DX on neovascularisation in the
CAM assay
The TPase inhibitors 7DX and 6A5BU were exposed to the
CAM of fertilised chicken eggs at 1 Wmol, 250 nmol and 100
nmol. At least 10 eggs were scored for each inhibitor concen-
tration in three independent experiments. Both 7DX and
6A5BU markedly prevented blood vessel formation in the
CAM test during a 2-day exposure time period (Figs. 3 and
4): when exposed to 7DX at 1 Wmol, 250 nmol or 100 nmol,
the eggs developed 34%, 34% or 18% less vessels than control
eggs. The TPase inhibitor 6A5BU a¡orded a reduction in new
vessel formation of 27%, 28% and 13% at 1 Wmol, 250 nmol
and 100 nmol, respectively (Fig. 3). The P values for the
1 Wmol and 250 nmol compound doses were 6 0.05 when
compared to control, whereas there was no statistical di¡er-
ence between the inhibitory values of 6A5BU and 7DX at
equimolar concentrations. Thus, 7DX and 6A5BU proved
equipotent as inhibitors of angiogenesis in the CAM assay.
Moreover, the reference anti-angiogenic fumagillin analogue
TNP-470, which is subject to phase I, II and III clinical trials
for a variety of solid tumours including Kaposi’s sarcoma,
a¡orded at a maximum tolerable dose of 100 nmol 21% in-
hibition of neovascularisation, under the same experimental
condition at which the subtoxic dose of 100 nmol 7DX af-
forded 34% inhibition (data not shown).
4. Discussion
7-DX should be considered a new lead compound with
pronounced inhibitory activity against thymidine phosphoryl-
ase and angiogenesis. To the best of our knowledge 7DX is
the ¢rst purine derivative that has been recognised as an e⁄-
cient inhibitor of a pyrimidine nucleoside phosphorylase (i.e.
TPase) and should be maintained in the future design of new
TPase inhibitors. Indeed, the CO-NH-CO functional entity in
the pyrimidine ring is also present in 7-DX. Moreover, the 5-
methyl part of thymine corresponds to the ethenyl moiety of
the pyrrole ring of 7DX, whilst the 6-amino group of 6AT
and 6A5BU corresponds to the NH of 7DX. The fact that
7DX contains a second (pyrrole) ring entity in the molecule
may open interesting perspectives in the design of more potent
purine-based TPase inhibitors. The inhibitory activity noted
for 7DX against TPase proved to be at the same order of
magnitude as 6A5BU, and supports our modelling studies
that revealed that 7DX mimics thymine and 6AT in the TPase
enzyme active site.
An important observation is that the TPase inhibition by
7DX and 6A5BU measured in the enzymatic assays closely
correlates with the anti-angiogenic e¡ect of these compounds
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Fig. 3. Inhibition of new blood vessel formation in the chicken egg
CAM test by 1000, 250 or 100 nmol of 7DX and 6A5BU.
Table 1
Inhibitory activity of 7DX and 6A5BU against thymidine phosphorylase as a function of compound concentration and incubation time
Inhibitor concentration (WM) 10 min incubation 60 min incubation
% of dThd remaininga % Inhibition of TPaseb % of dThd remaininga % Inhibition of TPaseb
7DX
1000 98 96 93 91
250 95 89 80 73
100 88 74 58 41
25 74 43 32 7
10 66 25 30 4
0 55 0 28 0
6A5BU
1000 100 100 100 100
250 96 91 83 76
100 94 87 80 71
25 89 76 59 44
10 82 60 42 20
0 55 0 28 0
aPercentage of thymidine remaining in the reaction mixture, as assessed by the HPLC chromatogram used to monitor the conversion of thymidine
to thymine.
bThe inhibition values were calculated from the percentage of thymidine remaining in the reaction mixture. The total conversion of dThd to Thy at
the di¡erent time points (10 and 60 min) was taken as 100% to calculate the inhibition values. At 10 min and 60 min approximately 50% (55 WM)
and 75% (73 WM) of thymidine was converted to thymine.
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observed in the CAM assay. These data provide additional
proof of the importance of TPase as an angiogenic agent, and
open interesting perspectives for the further exploitation of
TPase inhibition (i.e. 7DX) as potential anticancer and anti-
angiogenic agents.
A variety of modi¢cations are now being introduced at the
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Fig. 4. Chorioallantoic membrane of fertilised chicken eggs in the absence (A) or presence (B) of 1 Wmol 7DX.
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pyrrole ring of 7DX in an attempt to optimise the lead com-
pound as an inhibitor of TPase. These TPase inhibitors may
prove useful in combination therapy with those compounds
that have antiviral (i.e. BVDU, IdU, TFT) or antitumour (i.e.
5-FdU) potential but can be easily cleaved and thus inacti-
vated by TPase. TPase (and UPase) inhibitors may also help
in preventing the toxic side e¡ects of 5-£uorouracil (5-FU) by
suppressing the catabolism of 5-FdU (or 5-£uorouridine). It
would now be interesting to evaluate whether TPase inhibitors
such as 7DX favourably a¡ect the antiviral and/or antitumour
e¡ects of these di¡erent dThd analogues.
The ¢nding that 7DX has a marked anti-angiogenic activity
in the chicken egg CAM assay also opens interesting perspec-
tives for the further exploration of the TPase inhibitors as
potential anti-cancer agents. Therefore, an extensive synthesis
programme has now been generated to examine the potential
of 7DX derivatives from both an antiviral and antitumour
(i.e. anti-angiogenic) viewpoint, whether used alone (as single
agents) or in combination with other chemotherapeutics.
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